Onkologie Rheinsieg Praxisnetzwerk
- Address
- lock Available on a paid plan
Breast Cancer Research
The Onkologie Rheinsieg Praxisnetzwerk is actively studying a broad range of breast cancer settings, including early, locally advanced, metastatic, and triple-negative disease. The research focuses on improving treatment effectiveness, strengthening disease control after surgery, and testing new targeted and immunotherapy-based approaches.
- Early-stage and high-risk HER2-positive breast cancer studies are evaluating new neoadjuvant treatment options to improve response before surgery.
- HR-positive, HER2-negative breast cancer trials are examining endocrine-based combinations to reduce recurrence and extend disease-free survival.
- Triple-negative breast cancer research is centered on immunotherapy and antibody-drug conjugates to improve outcomes in aggressive disease.
Overall, the site is contributing to research that aims to refine personalized treatment strategies and improve long-term outcomes for patients with neoplasms in the breast.
Lung Cancer Research
Clinical trials at this Troisdorf site also address several forms of non-small cell lung cancer and small-cell lung cancer, including advanced, metastatic, and resectable disease. These studies are designed to test whether new combinations can improve survival, reduce recurrence, and enhance the impact of multimodal treatment.
- Metastatic non-small cell lung carcinoma and advanced non-squamous disease are being studied with newer targeted and antibody-based therapies.
- Stage III NSCLC trials are exploring combinations of chemoradiation, surgery, and immunotherapy to improve event-free survival.
- Extensive-stage small-cell lung carcinoma research is focused on evaluating treatment effectiveness in a fast-growing cancer type.
These studies reflect a strong emphasis on advancing care for thoracic malignancies through more effective and individualized treatment approaches.
Gastrointestinal and Liver Cancer Research
The site is also involved in trials for hepatocellular carcinoma, colon cancer, and rectal cancer, with a focus on improving outcomes after surgery and in advanced disease. Research in this area aims to better identify patients who may benefit from additional therapy and to strengthen disease-free survival.
- Advanced or unresectable hepatocellular carcinoma studies are evaluating new treatment strategies for difficult-to-treat liver cancer.
- Stage II colon cancer research is examining whether postoperative treatment can improve recurrence prevention in selected patients.
- Rectal cancer trials are contributing to broader efforts in gastrointestinal oncology to refine adjuvant treatment decisions.
These projects support research into more precise and effective care for digestive system cancers.
Digital Health and Treatment Optimization
Beyond drug-focused studies, the site is participating in research that explores how digital health solutions can support patients receiving cancer treatment. This work looks at symptom monitoring, treatment convenience, and ways to improve care delivery in routine practice.
- Digital patient monitoring studies are assessing whether remote symptom tracking can improve patient experience during treatment.
- Home-based care concepts are being explored to make immunotherapy more accessible and practical for selected patients.
- These trials aim to support better treatment adherence and more efficient cancer care pathways.
This area shows the site's interest in combining oncology with practical innovations that may improve day-to-day care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 32 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Onkologie Rheinsieg Praxisnetzwerk
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adjuvant Dynamic Marker-Adjusted Personalized Therapy: Ribociclib Plus Endocrine Therapy Versus Chemotherapy in HR+/HER2- Early Breast Cancer | WSG Westdeutsche Studiengruppe GmbH | Phase III | Not Recruiting | Jul 2019 | — |
IMP list
lock Showing 1 of 32 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ribociclib | 4 | Unknown | 2019-05-22 | 2026-04-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.